Biocryst Pharmaceuticals Inc BCRX
We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. 10-K, Item 1
- Headquarters
- Durham, NC
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $874.8M through the costs to a net profit of $263.9M · income statement of the 10-K
BCRX among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
30 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Divestiture of BioCryst Ireland Limited (“As described in Note 2 to the consolidated financial statements, the Company sold to Neopharmed Gentili S.p.A (“Neopharmed”) all of its equity interests in BioCryst Ireland, and amended and restated their existing intellectual property license agreement. In connection with the transaction, the Compa”). No longer listed: Table of Contents; Royalty Financing Obligations
-
Receivables +35.1% ($79.1M to $106.8M) vs revenue +94.1% ($450.7M to $874.8M), -59.0 pts apart
9 more checks with nothing to note
-
Cash from operations $347.4M vs net income $263.9M (FY ending Dec 31, 2025)
-
Inventory -33.3% ($8.1M to $5.4M) vs revenue +94.1% ($450.7M to $874.8M), -127.4 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
30 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
If the benefits of the Merger do not meet the expectations of investors or securities analysts, the market price of our common stock may decline. The market price of our common stock may decline as a result of the Merger if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
In addition, we do not know if, when, or how the FDA, Congress, or future judicial challenges may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
We may face competition from biosimilars, which may have a material adverse impact on the future commercial prospects of our biological products and product candidates. Even if we are successful in achieving regulatory approval to commercialize a biological product candidate faster than our competitors, we may face competition from…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
The process of manufacturing pharmaceutical products, devices and, in particular, biologics, is complex, highly regulated, and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error,…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $270.8M | $331.4M | $450.7M | $874.8M |
| Net income | −$247.1M | −$226.5M | −$88.9M | $263.9M |
| Operating cash flow | −$161.8M | −$95.1M | −$52.0M | $347.4M |
| Free cash flow | −$163.2M | −$97.3M | −$53.1M | $344.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$874.8M ▲ 94.1% in FY2025$263.9M in FY2025$344.9M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 4, 2026Quarterly results, Regulation FD disclosure 8-K items 2.02, 7.01
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Biocryst Pharmaceuticals Inc, Durham, NC · from the 10-K filed Feb 26, 2026
We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks.
- Headquarters
- Durham, NC
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.